|
1
|
Yan L, Zuo Y, Chen K, Xu Y, Le Y. Synthesis and Biological Evaluation of 5-Methylpyrimidine Derivatives as Dual Inhibitors of EGFR and Src for Cancer Treatment. HETEROCYCLES 2023. [DOI: 10.3987/com-23-14824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
|
2
|
Yan L, Zhang Y, Long Z, Le Y, Liu L. Microwave-Assisted Synthesis of Phenylisoxazole Derivatives via 1,3-Dipolar Cycloaddition. HETEROCYCLES 2022. [DOI: 10.3987/com-22-14654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
|
3
|
Yan L, Liu L, Wang Q, Rao N, Le Y. Development of 5-Trifluoromethylpyrimidine Derivatives as Dual Inhibitors of EGFR and Src for Cancer Therapy. HETEROCYCLES 2022. [DOI: 10.3987/com-21-14594] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
|
4
|
Zhang Y, Wang Q, Li L, Le Y, Liu L, Yang J, Li Y, Bao G, Yan L. Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells. J Enzyme Inhib Med Chem 2021; 36:1205-1216. [PMID: 34074193 PMCID: PMC8174486 DOI: 10.1080/14756366.2021.1933466] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Revised: 05/15/2021] [Accepted: 05/17/2021] [Indexed: 11/24/2022] Open
Abstract
In this paper, a set of 3-methylquniazolinone derivatives were designed, synthesised, and studied the preliminary structure-activity relationship for antiproliferative activities. All target compounds performed significantly inhibitory effects against wild type epidermal growth factor receptor tyrosine kinase (EGFRwt-TK) and tumour cells (A431, A549, MCF-7, and NCI-H1975). In particular, compound 4d 3-fluoro-N-(4-((3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)methoxy)phenyl)benzamide showed higher antiproliferative activities against all tumour cells than Gefitinib (IC50 of 3.48, 2.55, 0.87 and 6.42 μM, respectively). Furthermore, compound 4d could induce apoptosis of MCF-7 cells and arrest in G2/M phase at the tested concentration. Molecular docking and ADMET studies showed that compound 4d could closely form many hydrogen bonds with EGFRwt-TK. Therefore, compound 4d is potential to develop as novel anti-cancer drug.
Collapse
Affiliation(s)
- Yan Zhang
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, China
- State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China
- Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China
| | - Qin Wang
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, China
- State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China
- Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China
| | - Luolan Li
- State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China
- Shizhen College of Guizhou University of Traditional Chinese Medicine, Guiyang, China
| | - Yi Le
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, China
- State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China
- Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China
| | - Li Liu
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, China
- Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China
| | - Jing Yang
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, China
| | - Yongliang Li
- Faculty of Light Industry and Chemical Engineering, Guangdong University of Technology, Guangzhou, China
| | - Guochen Bao
- Institute for Biomedical Materials and Devices (IBMD), Faculty of Science, University of Technology Sydney, Sydney, Australia
| | - Longjia Yan
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, China
- State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China
- Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China
| |
Collapse
|
|
5
|
Yan L, Zhang D, Wang Q, Yang J, Zhang Q, Le Y, Liu L. Synthesis and Biological Evaluation of New Pyrimidine Derivatives as FAK Inhibitors for Development of Antitumor Agents. HETEROCYCLES 2021. [DOI: 10.3987/com-21-14526] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|